PR Newswire
ATLANTA, April 27, 2017
ATLANTA, April 27, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE:
CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that results from the
On-X aortic heart valve PROACT study will be presented in a late-breaking session at the American Association for Thoracic
Surgery (AATS) Centennial Meeting, which is being held April 29 to May 3, 2017 at the Hynes
Convention Center in Boston, MA.
Study Title: A Prospective Trial of Anticoagulation and Antiplatelet Strategies After
Mechanical Aortic Valve Replacement (PROACT)
Presenter: PROACT study principal investigator, John D.
Puskas, MD, Professor of Surgery, Icahn School of Medicine at Mount Sinai and Chairman, Department of Cardiovascular
Surgery, Mount Sinai Saint Luke's
Session Date/Time: Tuesday, May 2, 2017 from 12:45 –
2:00 PM EDT
About CryoLife
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing,
processing, and distribution of implantable living tissues and medical devices used in cardiac surgical procedures.
CryoLife markets and sells products in more than 80 countries worldwide. For additional information about CryoLife, visit
our website, www.cryolife.com.
Contacts:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryolife-announces-on-x-aortic-heart-valve-proact-study-results-to-be-presented-at-american-association-for-thoracic-surgery-centennial-meeting-300447008.html
SOURCE CryoLife, Inc.
